<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020175</url>
  </required_header>
  <id_info>
    <org_study_id>GCSF-940136</org_study_id>
    <nct_id>NCT01020175</nct_id>
  </id_info>
  <brief_title>Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Group for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      350 patients with early leukemias were assigned to receive peripheral blood or bone marrow
      transplantation; the occurrence of acute and chronic graft versus host disease, survival,
      transplantation-related mortality, and relapse rates were compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial was designed to investigate the safety and outcome of allogeneic
      filgrastim-mobilized PBPCT compared with allogeneic BMT in patients with standard-risk
      leukemia. A total of 350 patients between 18 and 55 years of age with acute leukemias in
      remission or chronic myelogenous leukemia in first chronic phase were randomized to receive
      either filgrastim-mobilized peripheral blood progenitor cells or bone marrow cells from
      HLA-identical sibling donors after standard high-dose chemoradiotherapy. The study was
      approved by the ethics committees of all participating centers, and all patients and donors
      gave informed consent before any study-related procedure was performed. Donor-recipient pairs
      were randomized to undergo either BMT or PBPCT. Randomization was carried out centrally at
      the International Institute for Drug Development (id2), Brussels, Belgium, and used the
      minimization method to allocate donor and recipient to allogeneic BMT or PBPCT. The
      randomization strata were as follows: diagnosis (chronic myeloid leukemia [CML] vs other
      diseases), sex mismatch of donor and recipient, and whether the donor was female and
      nulliparous. Follow-up visits were scheduled for 6, 12, 24, and 36 months after the date of
      transplantation.

      Neutrophil and platelet recovery occurred significantly faster after transplantation of
      peripheral blood progenitor cells than after bone marrow transplantation. Acute graft versus
      host disease of grades II-IV was significantly more frequent in recipients of peripheral
      blood progenitor cells than in recipients of marrow cells The cumulative incidence of chronic
      graft versus host disease was higher with peripheral blood progenitor cells than with bone
      marrow cells
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1995</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point of the study was the maximum grade of acute graft versus host (GVH) disease observed in the recipient.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVH disease grade II or above</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to acute GVH disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to an unsupported platelet count of 20 _ 109/L and 50 _ 109/L</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to absolute neutrophil count (ANC) of 0.5 x 10e9/L and 1 x 10e9/L</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of chronic GVH disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Bone marrow transplantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients received bone marrow transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral blood stem cell transplantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients received filgrastim-mobilized peripheral blood stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow transplantation</intervention_name>
    <description>Patients received bone marrow transplantation</description>
    <arm_group_label>Bone marrow transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood stem cell transplantation</intervention_name>
    <description>Patients received filgrastim-mobilized peripheral blood stem cell transplantation</description>
    <arm_group_label>Peripheral blood stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with either diagnosis of AML in first or second remission, in first untreated
             relapse (blast count in marrow &lt; 30%); ALL in first or second remission, in first
             untreated relapse (blast count in marrow &lt; 30%); CML in first chronic phase, in first
             accelerated phase (total blast and promyelocytes in marrow and or peripheral blood &lt;
             30%) or MDS (excluding RAEB-t).

          -  Age between 18 and 55 years.

          -  ECOG performance status between 0,1 or 2.

          -  HLA-identical sibling donor.

          -  Written informed consent.

        Exclusion Criteria:

          -  Serum creatinine more than 10% above the normal range for the centre.

          -  Left ventricular size and function abnormal.

          -  DLCO &lt; 50%.

          -  Bilirubin &gt; 2mg/dL (34.2 µmol/L).

          -  Splenectomised or splenic irradiation.

          -  Psychiatric, addictive, or any other disorder, which compromises ability to give truly
             informed consent for participation in this study.

          -  Currently receiving non-licensed drugs which may affect GVHD or engraftment.

          -  Pregnant or lactating women.

          -  Known sensitivity to E.coli derived products.

          -  HIV positive.

          -  Previously received BM/PBPC transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobert Schmitz, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Christian-Albrechts- Universita¨t, Kiel, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H Greinix, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allgemeines Krankenhaus, Vienna, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D Niederwieser, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Innsbruck, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Boogaerts, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Leuven, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Ferrant, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St Luc, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Arnold, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite der Humboldt Universität, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E Gluckman, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital St Louis, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N C Gorin, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoˆpital St Antoine, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N Frickhofen, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita¨t Ulm, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P Dreger, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian-Albrechts- Universita¨t, Kiel, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Zander, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Eppendorf, Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S McCann, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St James Hospital, Dublin, Ireland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Nagler, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah University Hospital, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Bacigalupo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Martino, Genova, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Gratwohl, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Apperley, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Hospital, London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N H Russell, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham City Hospital, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>O Ringde´n, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huddinge Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I Majolino, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale V Cervello-USL, Palermo, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J P Jouet, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Claude Huriez, Lille, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B Varet, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Necker, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Finke, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Albert-Ludwigs-Universität, Freiburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Smith, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds General Infirmary, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Bosi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Careggi, Firenze, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G Lambertenghi-Deliliers, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Padiglione G Marcora, Ospedale Maggiore di Milano, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K Kolbe, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinikum, Mainz, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T Ruutu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University CT. Rentral Hospital, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K A Bradstock), Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westmead Hospital, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B Lioure, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LCHRU de Hautepierre, Strasbourg, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T Hughes, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanson Centre for Cancer Research, Royal Adelaide Hospital, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Szer, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Melbourne Hospital, Parkville, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R Herrmann, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Perth Hospital, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>L Tru¨mper, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik, Homburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Falda, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Dipartimentale Trapianti di Midollo, Ospedale Molinette, Torino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Beksac, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara University Medical Facility, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E Nikiforakis, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evangelismos General Hospital, Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Abecasis, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Portugues de Oncologia Francisco Gentil, Lisboa, Portugal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Rowe, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Medical Center, Haifa, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Potter, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hospital Hampstead, London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H Wandt, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Klinik Nurnberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R Schwerdtfeger, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stiftung Deutsche Klinik f. Diagnostik, Wiesbaden, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Casper, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Rostock, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Pagliuca, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital, London, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Norbert Schmitz</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <organization>EBMT</organization>
  </responsible_party>
  <keyword>allogeneic transplantation</keyword>
  <keyword>Leukemia</keyword>
  <keyword>GvHD</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

